Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 1;20(5):463-471.
doi: 10.1097/COH.0000000000000965. Epub 2025 Jul 9.

Prospects for therapeutic T-cell vaccine strategies for HIV cure

Beatriz Mothe  1   2   3   4 , Christian Brander  3   4   5
Affiliations
Review

Prospects for therapeutic T-cell vaccine strategies for HIV cure

Beatriz Mothe et al. Curr Opin HIV AIDS. .

Abstract

Purpose of review: This review article aims to summaries the advances in T-cell vaccination as a component of HIV cure strategies. Recent clinical trials of therapeutic vaccination showing small but intriguing efficacy signals, provide the field with the data necessary to embark on informed combination strategies that build on these advances. The review focusses on aspects of T-cell immunogen design and vector use for vaccination, and discusses the effects of adjuvants and combination strategies on vaccine-induced immunity and their impact on virus control in people with HIV who undergo an analytical treatment interruption.

Recent findings: Vaccine-induced virus-specific T-cell immunity has been linked to relative control of viral replication in several recent clinical trials. Different immunogen concepts have also entered clinical trials, but for only a few are there immunogenicity and efficacy data available. New initiatives that leverage innate immune mechanisms show some interesting prospect to improve antiviral immunity. The available data also indicate that the preexisting T-cell immunity plays an important role in the strength and breadth of the vaccine-induced immunity.

Summary: With some efficacy data supporting the role of antiviral T-cell immunity, strategies that improve this response further can be delineated and incorporated into future, more potent combination approaches.

Keywords: HIV cure; T-cell vaccination; combination strategies; immunogen.

PubMed Disclaimer

Conflict of interest statement

B.M. and C.B. are inventors of the HTI T-cell immunogen, which has been licensed to Gilead Sciences.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Eron JJ, Little SJ, Crofoot G, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV 2024; 11:e146–e155. - PMC - PubMed
    1. Mamrosh JL, David-Fung E-S, Korber BTM, et al., editors. HIV molecular immunology. Theoretical biology and biophysics. Los Alamos, New Mexico; Los Alamos National Laboratory; 2024. LA-UR-24-32444.

    2. The Los Alamos HIV database contains an extensive collection of viral and immune-related data sets that have made HIV the human pathogen with the best characterized immune landscape, and provides essential guidance for HIV vaccine development.

    1. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007; 3:e157. - PMC - PubMed
    1. Rolland M, Manocheewa S, Swain JV, et al. HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. J Virol 2013; 87:5461–5467. - PMC - PubMed
    1. Kulkarni V, Rosati M, Valentin A, et al. HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One 2013; 8:e60245. - PMC - PubMed

MeSH terms